Creos International suspends shares

Article

X-ray generator developer Creos International of Fife, Scotland, has been encountering financial problems of late. The company last month requested that its shares be suspended from trading on the Alternative Investment Market of the U.K. while it

X-ray generator developer Creos International of Fife, Scotland, has been encountering financial problems of late. The company last month requested that its shares be suspended from trading on the Alternative Investment Market of the U.K. while it “considers its financial position.” The company has closed its subsidiary, Creos Limited, and is seeking the appointment of a provisional liquidator.

The company’s compact x-ray generator technology will live on, however. In December, Creos Limited’s U.S. subsidiary, Creos Inc., sold its business and assets to Colorado businessman Peter Cooper, who founded a new, private company, Creos Technologies of Englewood, CO. Creos Technologies employs 33 people and manufactures the high-powered, high-frequency x-ray generators initially developed by Creos International (SCAN 7/13/94). Creos International holds a residual interest in the new company.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.